MARKET WIREInvesting.com • 1d ago
Newamsterdam Pharma stock hits 52-week low at 21.02 USDInvesting.com report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
Why NAMS Stock dropped -2.49% Today — RQD Quant Desk Flash
$19.56 -2.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $19.44
NewAmsterdam Pharma Company N.V. (NAMS) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.40B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NAMS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NAMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $19.56 (-2.49% 1D, market cap $2.40B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NAMS ranks #900 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NAMS compare to SUPN and PHVS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NAMS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SUPN (Supernus Pharmaceuticals Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -4.5%, cap $2.44B) and PHVS (Pharvaris N.V.) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, PBH leads on earnings multiple (12.1x) while PBH leads on capital efficiency (13.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NAMS?
▼
Per NAMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001936258), NewAmsterdam Pharma Company N.V. generated $22.5M in revenue (-50.6% YoY), -$203.0M in net income, and -$147.8M in free cash flow against $769.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $19.43 (-0.64%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAMS)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY NAMS SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)
Altman Z-Score 15.94 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$20.19+6.5% Next Q
34
Q2 (-2Q)Grade E$21.50-4.7% Next Q
31
Q3 (-1Q)Grade E$20.50-4.6% Next Q
29
CurrentGrade E$19.56-10.5% Hist 90D α
26
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NAMS Turnaround Squeeze
While NAMS currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.58) and Max Pain ($20.54) forces dealer call-delta covering toward $44.32.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NAMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NAMS Stock dropped -2.49% Today — RQD Quant Desk Flash
NewAmsterdam Pharma Company N.V. (NAMS) dropped -2.49% to $19.56, trading at 2% of its 52-week range ($19.13 – $42.21). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($19.13 – $42.21) with RSI-14 at 41.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.1% around $19.56 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NAMS Headlines & Catalysts
MARKET WIREwww.debelegger.nl • 1d ago
NewAmsterdam Pharma (NAMS) Stock Price, Chart & Analysiswww.debelegger.nl report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst PredictionsSimply Wall St report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
The Technical Signals Behind (NAMS) That Institutions FollowStock Traders Daily report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
NewAmsterdam Pharma (NAMS) Climbs 2.78% to $21.07 as Shares Push Toward Upper Range - Price Gap Fillhttps://www.siam.in/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
Newamsterdam Pharma stock hits 52-week low at 19.57 USD By Investing.comInvesting.com India report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
NewAmsterdam Pharma (NAMS) Ticks Higher: Shares Gain 1.48% to $21.57 - Gap and Reversehttps://www.dars.gov.et/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
RISK WATCHhttps://www.dars.gov.et/ • 2d ago
NAMS Q2 2026 Earnings: Wider-Than-Expected Loss Meets a Mutedly Positive Stock Reaction - Analyst Consensus Shifthttps://www.dars.gov.et/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 20d ago
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?NewAmsterdam Pharma recently dosed the first participant in SPINOZA, a Phase 2b, randomized, double-blind, placebo-controlled trial evaluating its CETP inhibitor obicetrapib in about 400 people with preclinical Alzheimer
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAMS)
- ✓Walkthrough of NAMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NAMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.49%⚡ TESTING RESISTANCE
2026-11-03O $20.76H $20.76L $19.56C $19.56VOL 1.14M
RES: $20.48SUP: $16.66SMA50: $22.58SMA200: $29.69
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NAMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -50.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NAMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NAMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAMS)
Health Care Rank #900 of 1015
⚔️ SUPN vs NAMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NAMS vs. SUPN, PHVS, BHVN, PBH)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, NewAmsterdam Pharma Company N.V. (NAMS) ranks #900 by composite RQD confidence (26/100, grade E) and #223 by equity capitalization ($2.40B). Within this direct 5-issuer industry benchmark cohort, PBH leads on earnings valuation at 12.1x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with NAMS at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NAMS
ACTIVE
NewAmsterdam Pharma Company N.V. | E | 26/100 | — | — | -35.0% | -2.49% | $2.40B | Benchmark Subject |
| SUPN Supernus Pharmaceuticals Inc. | D+ | 57/100 | — | 89.6% | -4.5% | +0.19% | $2.44B | /supn-vs-nams → |
| PHVS Pharvaris N.V. | C- | 59/100 | — | — | — | 0.00% | $2.34B | /phvs-vs-nams → |
| BHVN Biohaven Ltd. | D | 44/100 | — | — | -35.0% | -1.69% | $2.33B | /bhvn-vs-nams → |
| PBH Prestige Consumer Healthcare Inc. | C | 62/100 | 12.1x | 54.7% | 13.8% | +1.37% | $2.32B | /pbh-vs-nams → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001936258 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewAmsterdam Pharma Company N.V. (NAMS) reported GAAP revenue of $22.5M (-50.6% vs. FY2024 revenue of $45.6M , and +59.7% cumulative change since FY2023) , GAAP net income of -$203.0M, operating cash flow of -$147.8M, and free cash flow of -$147.8M (+6.8% YoY). On the balance sheet, NAMS closed FY2025 with $769.3M in total assets against $0 in total debt (Altman Z-Score: 15.94, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $22.5M | -$203.0M | -$147.8M | -$147.8M | $769.3M | — |
| FY2024 (FY) | 2024-12-31 | $45.6M | -$242.0M | -$158.6M | -$158.6M | $864.6M | — |
| FY2023 (FY) | 2023-12-31 | $14.1M | -$177.0M | -$141.2M | -$141.2M | — | — |
3. NAMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NAMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $19.56 (-2.49% 1D, market cap $2.40B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NAMS ranks #900 in composite RQD confidence.
How does NAMS compare to SUPN and PHVS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NAMS carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SUPN (Supernus Pharmaceuticals Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -4.5%, cap $2.44B) and PHVS (Pharvaris N.V.) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $2.34B). Among the 5-stock peer group, PBH leads on earnings multiple (12.1x) while PBH leads on capital efficiency (13.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NAMS?
Per NAMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001936258), NewAmsterdam Pharma Company N.V. generated $22.5M in revenue (-50.6% YoY), -$203.0M in net income, and -$147.8M in free cash flow against $769.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NAMS trading relative to its 50-day, 200-day, and 52-week technical levels?
NAMS last traded at $19.56 (-2.49% on volume of 2,006,298 shares), positioning the stock -13.37% below its 50-day simple moving average ($22.58) and -34.12% below its 200-day simple moving average ($29.69). Across its 52-week range of $19.13 to $42.21, NAMS sits at the 1.9% percentile with a 14-day RSI of 41.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($17.39 to $21.73).
ROARABLE RATING BRIEF • RQD 26/100 (E)
✓ SEC XBRL & RQD VERIFIED
NAMS — NewAmsterdam Pharma Company N.V.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
NewAmsterdam Pharma Company N.V. (NAMS) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $19.56 (-2.49% 1D, market capitalization $2.40B).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -5.96%.
- Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 15.94, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
NewAmsterdam Pharma Company N.V. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue across the financial periods (see Financial Trend) indicates the company generates limited top-line sales relative to its operating losses.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NewAmsterdam Pharma Company N.V. (NAMS) reported $22.5M in annual revenue (up from $45.6M in FY2024, -50.6% YoY) and -$203.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.1M revenue, -$177.0M net income) through FY2025, NAMS scaled operating cash flow to -$147.8M and free cash flow to -$147.8M, backed by $769.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.96% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $19.13 – $42.21 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NAMS carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can NAMS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $22.5M and free cash flow of -$147.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NAMS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NAMS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for NewAmsterdam Pharma Company N.V. (NAMS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 1d ago
Newamsterdam Pharma stock hits 52-week low at 21.02 USD Investing.com report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.debelegger.nl • 1d ago
NewAmsterdam Pharma (NAMS) Stock Price, Chart & Analysis www.debelegger.nl report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions Simply Wall St report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
The Technical Signals Behind (NAMS) That Institutions Follow Stock Traders Daily report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
NewAmsterdam Pharma (NAMS) Climbs 2.78% to $21.07 as Shares Push Toward Upper Range - Price Gap Fill https://www.siam.in/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
Newamsterdam Pharma stock hits 52-week low at 19.57 USD By Investing.com Investing.com India report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
NewAmsterdam Pharma (NAMS) Ticks Higher: Shares Gain 1.48% to $21.57 - Gap and Reverse https://www.dars.gov.et/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago
NAMS Q2 2026 Earnings: Wider-Than-Expected Loss Meets a Mutedly Positive Stock Reaction - Analyst Consensus Shift https://www.dars.gov.et/ report covering NewAmsterdam Pharma Company N.V. (NAMS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NAMS Bull vs. Bear Conversation Board — What's Your Call at $19.56?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NAMS 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $26.48 (+32.0%)
📌 Pinned Debate Altman Z-Score of 15.94 indicates a strong balance-sheet safety signal, with $490.0M in cash at FY 2025.
Long NAMS at $20.06 targeting $26.48. Altman Z-Score of 15.94 indicates a strong balance-sheet safety signal, with $490.0M in cash at FY 2025.. Institutional whale score is 4/20 and the risk/reward vs. the $19.13 52-week low is skewed heavily in favor of bulls.
ArenaChamp_24 🐂 BULL
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $17.05 (-15.0%)
Spot @ $20.06 Operating losses of -$225.7M on $22.5M revenue in FY 2025, with ROIC of -35%, keep the RQD grade at E.
Here is the bear case nobody on the bull side wants to address on NAMS: Operating losses of -$225.7M on $22.5M revenue in FY 2025, with ROIC of -35%, keep the RQD grade at E.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.